These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37030031)

  • 21. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients.
    Lip GYH; Keshishian A; Li X; Hamilton M; Masseria C; Gupta K; Luo X; Mardekian J; Friend K; Nadkarni A; Pan X; Baser O; Deitelzweig S
    Stroke; 2018 Dec; 49(12):2933-2944. PubMed ID: 30571400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of left atrial appendage closure with Watchman for non-valvular atrial fibrillation patients in Japan.
    Kamae I; Zhong Y; Hara H; Inoue K; Yasaka M; Reddy VY; Holmes DR; Sakurai M; Gavaghan MB; Amorosi SL; McGovern AM; Priest V; Inoue S; Shibahara H; Akehurst RL
    J Med Econ; 2023; 26(1):1357-1367. PubMed ID: 37819734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study.
    Durand M; Schnitzer ME; Pang M; Carney G; Eltonsy S; Filion KB; Fisher A; Jun M; Kuo IF; Renoux C; Paterson JM; Quail J; Matteau A;
    CMAJ Open; 2020; 8(4):E877-E886. PubMed ID: 33355273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
    Coyle D; Coyle K; Cameron C; Lee K; Kelly S; Steiner S; Wells GA
    Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic Evaluation of Direct Oral Anticoagulants Compared to Warfarin for Venous Thromboembolism in Thailand: A Cost-Utility Analysis.
    Niyomsri S; Nimworapan M; Wongcharoen W; Dilokthornsakul P
    Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36833871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug Utilization Pattern of Oral Anticoagulants in Patients with Atrial Fibrillation: A Nationwide Population-Based Study in Korea.
    Lee MY; Han S; Bang OY; On YK; Jang SW; Han S; Ryu J; Park YJ; Kang S; Suh HS; Kim YH
    Adv Ther; 2022 Jul; 39(7):3112-3130. PubMed ID: 35524839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Decision Analysis of Percutaneous Left Atrial Appendage Occlusion Relative to Novel and Traditional Oral Anticoagulation for Stroke Prevention in Patients with New-Onset Atrial Fibrillation.
    Micieli A; Wijeysundera HC; Qiu F; Atzema CL; Singh SM
    Med Decis Making; 2016 Apr; 36(3):366-74. PubMed ID: 26139448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for atrial fibrillation in Portugal.
    Costa J; Fiorentino F; Caldeira D; Inês M; Lopes Pereira C; Pinheiro L; Vaz-Carneiro A; Borges M; Gouveia M
    Rev Port Cardiol; 2015 Dec; 34(12):723-37. PubMed ID: 26616542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study.
    Van Ganse E; Danchin N; Mahé I; Hanon O; Jacoud F; Nolin M; Dalon F; Lefevre C; Cotté FE; Gollety S; Falissard B; Belhassen M; Steg PG
    Stroke; 2020 Jul; 51(7):2066-2075. PubMed ID: 32539675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States.
    Baker CL; Dhamane AD; Mardekian J; Dina O; Russ C; Rosenblatt L; Lingohr-Smith M; Menges B; Lin J; Nadkarni A
    Adv Ther; 2019 Jan; 36(1):162-174. PubMed ID: 30499067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
    Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation Based on Available "Real-World" Evidence: The Italian National Health System Perspective.
    Lorenzoni V; Pirri S; Turchetti G
    Clin Drug Investig; 2021 Mar; 41(3):255-267. PubMed ID: 33587284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery Disease.
    Lopes RD; Thomas L; Di Fusco M; Keshishian A; Luo X; Li X; Masseria C; Friend K; Mardekian J; Pan X; Yuce H; Jones WS
    Am J Cardiol; 2021 Jun; 148():69-77. PubMed ID: 33667438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
    Amin A; Keshishian A; Dina O; Dhamane A; Nadkarni A; Carda E; Russ C; Rosenblatt L; Mardekian J; Yuce H; Baker CL
    J Thromb Thrombolysis; 2019 Aug; 48(2):240-249. PubMed ID: 30924051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
    Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J
    Curr Med Res Opin; 2017 Oct; 33(10):1745-1754. PubMed ID: 28849676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
    Rahme E; Godin R; Nedjar H; Dasgupta K; Tagalakis V
    Thromb Res; 2021 Jul; 203():121-130. PubMed ID: 34000493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
    Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
    JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 39. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation--a real patient data analysis in a Hong Kong teaching hospital.
    Chang AM; Ho JC; Yan BP; Yu CM; Lam YY; Lee VW
    Clin Cardiol; 2013 May; 36(5):280-5. PubMed ID: 23494609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain.
    Escobar Cervantes C; Martí-Almor J; Cabeza AIP; Bowrin K; Llorac Moix A; Genís Gironès M; Gasche D; Millier A; Tardu J; Toumi M; Briere JB
    PLoS One; 2022; 17(4):e0266658. PubMed ID: 35443000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.